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Abstract
Background: End stage renal disease patients are at risk of Vancomycin-Resistant Enterococcus
(VRE) infections. The first reports of VRE isolation were from hemodialysis patients. However, to
date, VRE fecal colonization rates as well as associated risk factors in kidney transplant patients
have not yet been established in prospective studies.
Methods: We collected one or two stool samples from 280 kidney transplant patients and
analysed the prevalence of VRE and its associated risk factors. Patients were evaluated according
to the post-transplant period: group 1, less than 30 days after transplantation (102 patients), group
2, one to 6 months after transplantation (73 patients) and group 3, more than 6 months after
transplantation (105 patients).
Results: The overall prevalence rate of fecal VRE colonization was 13.6% (38/280), respectively
13.7% for Group 1, 15.1% for group 2 and 12.4% for group 3. E. faecium and E. faecalis comprised
50% of all VRE isolates. No immunologic variables were clearly correlated with VRE colonization
and no infections related to VRE colonization were reported.
Conclusion: Fecal VRE colonization rates in kidney transplant patients were as high as those
reported for other high-risk groups, such as critical care and hemodialysis patients. This high rate
of VRE colonization observed in kidney transplant recipients may have clinical relevance in
infectious complications.
Background
Despite improvements in surgical techniques and devel-
opment of new immunosuppressive drugs, infections
remain the second most frequent cause of mortality in
kidney transplant patients.
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Enterococci are frequent causative agents of both nosoco-
mial and community acquired infection in transplant
patients, including bacteremia, urinary tract infections
and surgical site infections [1]. In the past two decades,
resistance to glycopeptides has emerged in an epidemic
fashion and is now endemic in many countries. One of
the first descriptions of Vancomycin-Resistant Enterococ-
cus (VRE) was in patients with end stage renal disease
(ESRD) [2] and such patients seem particularly suscepti-
ble to colonization.
The prevalences of VRE colonization and infection are
especially high among intensive care unit (ICU) patients
and in oncology and organ transplant wards. The preva-
lence of VRE in liver transplant patients range from 3.4 %
in patients in the waiting list [3] to as high as 44 % after
transplantation [4].
Kidney transplant patients may be prone to developing
high rates of VRE colonization and infection due to fre-
quent use of antibiotics, particularly vancomycin both
before and after transplantation. However, although kid-
ney transplantation is the solid organ transplantation
most frequently performed, little is known about preva-
lence and risk factors for fecal colonization by VRE among
these patients.
The aim of this study was therefore to evaluate the preva-
lence of fecal colonization by VRE among kidney trans-
plant recipients in three different post-transplantation
periods and identify risk factors related to fecal VRE colo-
nization among kidney transplant recipients.
Methods
This study was conducted at the Hospital do Rim e
Hipertensão (HRH), affiliated to the Federal University of
São Paulo (UNIFESP), Brazil, and was approved by the
Institutional Ethics Committee. All patients gave a written
informed consent to participate in the study.
One gram of IV cephalothin is administered immediately
before surgery and every 6 hours for the first 48 hours. Tri-
methoprim-sulfamethoxazole 80 mg-400 mg is pre-
scribed in a single daily oral dose for 6 months, for urinary
tract infections prophylaxis.
The immunosuppressive maintenance regimen plan con-
sists mainly of azathioprine, prednisone and cyclosporin
or alternatively tacrolimus, rapamycin and mycopheno-
late Mofetil, in different combinations. For anti-rejection
treatment, high doses of corticosteroids, antilymphocyte
globulin and monoclonal antibodies are used for short
periods. Ganciclovir is not given as routine prophylaxis
but is used for the treatment of patients with positive CMV
antigenemia.
Patients
VRE colonization was investigated in three different
groups of patients, in three distinct post-transplant peri-
ods, as follows: 1) Recent recipients, up to 30 days after
transplantation (group 1); 2) Between 1 and 6 months of
transplantation (group 2); 3) After 6 months of transplan-
tation (group 3). We controlled patient register numbers
in order to avoid the same patient being evaluated in dif-
ferent groups.
In Group 1, patients first samples were collected while
they were still in hospital, shortly after transplantation
and the second sample for the same patient was collected
occasionally after discharge. Groups 2 and 3 patients were
evaluated during routine follow up appointment in an
outpatient facility.
VRE colonization evaluation
For each patient we planned to collect two stool speci-
mens with a one-week-interval. For Group 1 patients, the
first specimen was collected within one week of transplan-
tation. The specimens were processed at the Special Clini-
cal Microbiology Laboratory (LEMC) of the Infectious
Diseases Department of UNIFESP. Patients were consid-
ered to be colonized by VRE if species of VRE were identi-
fied in at least one of the stool samples tested.
Stool specimens were collected in sterile receptacles and
plated on media specifically selective for VRE (azide
blood agar, OXOID-England, with 6 μg/mL of vancomy-
cin)[5]. Enterococcus isolates were identified to the species
level with the conventional biochemical tests as described
by Facklam, Sham and Teixeira [6]. All samples were
investigated by disk diffusion NCCLS [7] for resistance to
ampicillin, vancomycin, teicoplanin, streptomycin and
gentamicin. MICs of vancomycin, teicoplanin, ampicillin,
streptomycin and gentamicin were determined by Etest
(AB Biodisk, Solna, Sweden) for isolates with vancomycin
inhibition zones ≤ 16 mm. Isolates were categorized
according to the National Committee for Clinical Labora-
tory Standards (NCCLS) breakpoints [7]. ATTC strains
Staphylococcus aureus 29213 and E. faecalis 29212 were
used as controls.
Demographic data and risk factors
The following variables were obtained and defined for
each patient, by direct interviews and chart review: name;
gender; age; race; primary renal disease; modality of renal
replacement therapy employed immediately before trans-
plantation (hemodialysis, peritoneal dialysis or conserva-
tive treatment); the total length of time in months on
dialysis therapy before transplantation, considering all
the methods and treatments. For Group 1 patients, antibi-
otic consumption (including vancomycin use) was notBMC Infectious Diseases 2006, 6:133 http://www.biomedcentral.com/1471-2334/6/133
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analyzed, since data was not considered accurate using
direct interviews.
The following medical reports regarding transplantation
were collected: by chart reviews seropositivity to hepatitis
B and C at the time of the transplantation, using Ag Hbs
and anti-HCV antibodies (immunofluorescence); the
number of blood transfusions before transplantation;
retransplantation; length of stay, calculated as the sum of
in hospital days; dialysis therapy after transplantation, if
there was more than one hemodialyses session; human
leukocyte antigen (HLA) compatibility, divided into two
groups: Identical and haploidentical HLA; and distinct
HLA living donor and deceased donor; use of monoclonal
(anti-CD3) or polyclonal antibodies (OKT3/Thymoglob-
ulin®) for induction therapy as well as for treatment of epi-
sodes of corticosteroid-resistant acute rejection; pulse
therapy using intravenous methylprednisolone for treat-
ment of acute rejection episodes, with one gram daily for
3 to 5 days; use of mycophenolate mofetil; Surgical re-
intervention; use of trimethoprim-sulfamethoxazole; use
of vancomycin (for groups 2 and 3 only); use of ganciclo-
vir for at least 7 days, as therapy for cytomegalovirus infec-
tion and the total duration of hospitalization (total
number of in-hospital days from the first day of transplan-
tation to specimen collection, considering all admissions)
(Table 3).
Statistical analysis
To study the risk factors for VRE colonization, the param-
eters were initially evaluated by univariate analysis, using
the chi-square test or the Fisher exact test for categorical
variables and the Student's t test for continuous variables.
The tests were two-tailed and the significance level was set
at p < 0.05. Multivariate logistic regression analysis was
performed to evaluate the variables associated with VRE
colonization. Both univariate and multivariate analysis
were performed for each group separately. The independ-
ent variables tested were those with p value less than 0.30
in previous univariate analysis. The statistical program
SPSS, version 10.0 for Windows was used in the analyses.
Results
Between June 2001 and March 2003, 280 kidney trans-
plant recipients were studied: 102 in group 1 (less than 30
days after transplantation), 73 in group 2 (1 to 6 months
after transplantation – median 2 months (2–5 months)
and 105 in group 3 (more than 6 months after transplan-
tation – median 20 months (6–206 months). The general
characteristics of the studied population are shown in
Table 1.
Two stool specimens were collected from 41 patients in
group 1 (40%), 41 patients (56%) in group 2 and 72
patients (69%) in group 3. The remaining patients had
only one specimen collected. Group 1 patients first stool
samples were collected while patients were still in the hos-
pital. For group 2 and 3 patients first stool samples were
collected as they came for regular follow up appoint-
ments. The major reason for not collecting a second sam-
ple in all groups was that despite offering money support
for public transportation, patients did not return for a sec-
ond consultation only for protocol purposes. In group 1,
60% of specimens were collected more than 7 days apart;
and the second sample was excluded from analysis. Group
2 and 3 samples were collected with a maximum interval
of 30 days.
A total of 38 patients had VRE fecal colonization among
the 280 patients evaluated, with an overall prevalence rate
of 13.6%. Of these 38 patients, fourteen (36.8%) were
Table 1: General characteristics of kidney transplant recipients
Number of Patients 280 (100)
Group 1 (less than 30 days after transplantation) 102 (36.4)
Group 2 (1 to 6 months after transplantation) 73 (26)
Group 3 (> 6 months after transplantation) 105 (37.5)
Gender
Male 163 (58.2)
Race
White 187 (66.7)
Non-white 93 (33.2)
Primary renal disease
Indeterminate 137 (48.9)
Hypertension 61 (21.7)
Glomerulonephritis 44 (15.7)
Diabetes Mellitus 11 (3.9)
Others 27 (9.6)
Pre transplant treatment
Hemodialysis 262 (93.5)
CAPD 12 (4.2)
Conservative 6 (2.1)
Kidney donor
HLA I and II 160 (57.1)
HLA III and deceased donor 120 (42.8)
Immunosuppressive drugs **
Mycophenolate mofetil 59 (33.1)
OKT3/Thymoglobulin® 13 (7.3)
Methylprednisolone pulse 58 (32.5)
Surgical reexploration 14 (5)
Post-transplantation dialysis 46 (16.4)
Serology
Hepatitis C virus 31 (11)
Hepatitis B virus 7 (2.5)
Post-transplantation antimicrobial drugs ** 117 (65.7)
Vancomycin ** 11 (6.1)
Ganciclovir ** 18 (10.1)
** Immunosuppressive drugs, post-transplantation antimicrobial 
drugs, vancomycin and ganciclovir: just for groups 2 and 3.
CAPD = chronic ambulatory peritoneal dialysis; HLA I = identical 
human leukocyte antigen;
HLA II = haplo-identical human leukocyte antigen; HLA III = distinct 
human leukocyte antigen;
Values are expressed as N (%).BMC Infectious Diseases 2006, 6:133 http://www.biomedcentral.com/1471-2334/6/133
Page 4 of 7
(page number not for citation purposes)
from group 1, eleven (28.9%) from group 2, and thirteen
(34.2%) from group 3. Fecal colonization rates were
13.7% in group 1, 15.1% in group 2 and 12.4% in group
3.
Fifty percent of all VRE isolates were either E. faecalis or E.
faecium (Table 2). E. gallinarum colonization accounted
for 28.9% of all colonized patients (11 patients). E. fae-
cium was isolated from ten patients (26.3%) and E. faeca-
lis, from nine patients (23.6%). For 29 out of 38 positive
patients, the first collected specimen tested positive, while
9 (24%) had the first specimen negative and the second
positive.
In the univariate analysis (Table 3), the only variable asso-
ciated with fecal VRE colonization was chronic ambula-
tory peritoneal dialysis (CAPD) for group 3 (15.4% vs
1.1%, p = 0.006).
Multivariate logistic regression disclosed CAPD, hepatitis
B seropositivity and vancomycin use (Table 4) as inde-
pendent risk factors for fecal VRE colonization for group 3
patients only.
Discussion
VRE infection is a growing problem in specific groups of
patients. However there is no data of VRE colonization
prevalence in kidney transplant patients. Our study dis-
closed an unexpected high rate of VRE fecal colonization
in such patients similar in the 3 groups of patients, in dif-
ferent pos-transplantation periods. This high rate cannot
be compared to a healthy Brazilian population, since no
data is currently available. On the other hand, very similar
rates were observed in Brazilian risk groups [8,11].
In group 1 (less than 30 days after transplantation), fecal
VRE carriage probably represented colonization within
the dialysis setting. In this group, we excluded from anal-
ysis positive specimens that were collected more than 7
days apart because colonization could be associated with
factors related to hospital admission, such as hospital
transmission. In a simultaneous Brazilian study of 320
patients from an outpatient dialysis program, a prevalence
rate of fecal VRE colonization of 14.4% was observed [8],
very similar to overall rate we observed in transplant
patients.
We found VRE prevalence rates of 15.1% in group 2 (1 to
6 months after transplantation) and 12.4% in group 3
(more than 6 months after transplantation), which are
very similar to group 1 rates. This shows that the risk fac-
tors related to transplantation, such as the net state of
immunosuppression, cumulative use of antimicrobial
drugs and longer hospitalization (groups 2 and 3) were
not related to increased VRE prevalence over time. The
study design, however, did not allow us to evaluate
whether VRE colonization was persisting or whether
acquisition from outside the hospital was occurring. If the
patients had been monitored using surveillance cultures
during this six-month period, we would have been able to
affirm with certainty whether colonization was persisting
or not. On the other hand, it is possible that colonization
persists over time, as has been described by others [9] and
persistence may have been amplified as a consequence of
the use of antimicrobial drugs or the net state of immuno-
suppression.
Our rates of fecal colonization were as high as those found
in surveillance studies in Intensive Care Unit patients.
Fridkin et al. [10], in a prospective study including 126
adult ICU patients in 60 American hospitals between Jan-
uary 1996 and July 1999, found an average prevalence
rate of 10%. A similar rate has been disclosed in a single
center Brazilian ICU study (14.5%) [11]. Such similar
rates may be explained by the presence of similar risk fac-
tors for VRE acquisition, such as antimicrobial use, fre-
quent and prolonged hospitalization and severity of
underlying diseases.
Fifty percent of the VRE positive patients were colonized
by faecalis/faecium species of enterococci. E. gallinarum is a
species with intrinsic resistance to vancomycin and seems
to be very frequently found in Brazilian studies, in con-
trast with other studies, and contributed to 28.9% of VRE
positive samples in this study. Barbosa et al. [8] studying
dialysis patients, observed that 57.1% of the VRE isolates
Table 2: Enterococcus species isolated from kidney transplant recipients
Species Group 1 Group 2 Group 3 Total
E. faecalis 81- 9  ( 2 3 . 6 )
E. faecium 2 3 5 10 (26.3)
E. gallinarum 2 5 4 11 (28.9)
E. casseliflavus 223 7  ( 1 8 . 4 )
E. raffinosus 1 1 (2.6)
Total number of VRE-positive patients 14 (36.8) 11 (28.9) 13 (34.2) 38 (100)
Values are expressed as N or N (%).BMC Infectious Diseases 2006, 6:133 http://www.biomedcentral.com/1471-2334/6/133
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were E. gallinarum and 10.7% were E. casseliflavus. Thus,
our transplant patients seem to have more faecalis/faecium
species of enterococci than patients on dialysis (50% vs.
28.6%). Camargo et al. [11], in a Brazilian ICU, found
that 84% of VRE species recovered from fecal specimens
of critical patients were E. gallinarum. These findings con-
trast with clinical disease due to Enterococci, since it is esti-
mated that 80–90% of the human enterococcal infections
are caused by E. faecalis, 10–15% by E. faecium and less
than 5% by other species [12]. On the other hand, E. cas-
seliflavus and E. gallinarum have recently been reported as
causative agents of clinical disease [13,14]. Reid et al. [15]
recently described 20 cases of bacteremia caused by E. gall-
inarum or E. casseliflavus/flavescens, which were observed in
the Mayo Clinic between 1992 and 1998. It is not possible
to affirm that this is a tendency and these unusual agents
Table 4: Final logistic regression model for risk factors for fecal VRE colonization in kidney transplant patients.
Factors Group of patients Coefficient Standard error p Likelihood ratio 95% confidence interval
Lower limit Upper limit
CAPD 3 3.245 1.296 0.012 25.667 2.024 325.491
Hepatitis B 3 2.552 1.476 0.084 12.833 0.711 231.752
Vancomycin 3 2.041 0.844 0.016 7.700 1.471 40.293
Constant -2.552 0.424 0.000
CAPD = chronic ambulatory peritoneal dialysis.
Table 3: General characteristics of kidney transplant recipients, for group 1, 2 and 3
Group 1 Group 2 Group 3
Characteristic VRE+ VRE - p value VRE+ VRE - p value VRE+ VRE - p value
Gender
Male 10(71.4) 58(65.9) 0.769 6(54.5) 35(56.5) 1 4(30.8) 50(54.3) 0.111
Ages, in years 43 ± 14 39 ± 13 0.579 40 ± 10 41 ± 13 0.857 41 ± 11 42 ± 10 0.789
Race
White 11(78.6) 61(69.3) 7(63.6) 41(66.1) 12(92.3) 55(59.8)
Non-white 3(21.4) 27(30.6) 0.494 7(63.6) 21(33.9) 0.791 1(7.7) 37(40.3) 0.122
Primary renal disease
Indeterminate 8(57.1) 45(51.1) 6(54.5) 32(51.6) 7(53.8) 39(42.4)
Hypertension 3(21.4) 17(19.3) 3(27.3) 16(25.8) 22(23.9)
Glomerulonephritis 3(21.4) 15(17) 6(9.7) 3(23.1) 17(18.5)
Diabetes Mellitus 4(4.5) 3(4.8) 1(7.7) 3(3.3)
Others 7(8) 0.934 2(18.2) 5(8.1) 0.752 2(15.4) 11(12) 0.195
Pre transplant treatment
Hemodialysis 13(92.9) 79(89.8) 11(100) 58(93.5) 10(76.9) 91(98.9)
CAPD 7(8) 2(3.2) 2(15.4) 1(1.1)
Conservative 1(7.1) 2(2.3) 0.269 2(3.2) 1 1(7.7) 0.006
Kidney donor
HLA I and II 6(42.9) 55(62.5) 5(45.5) 36(58.1) 8(61.5) 50(54.3)
HLA III and deceased donor 8(57.1) 33(37.5) 0.164 6(54.5) 26(41.9) 0.518 5(38.5) 42(45.7) 0.626
Surgical reexploration 1(7.1) 1(1.1) 0.257 1(9.1) 5(8.1) 1 2(15.4) 4(4.3) 0.16
Mycophenolate mofetil 3(27.3) 31(50) 0.164 4(30.8) 21(22.8) 0.504
OKT3/Thymoglobulin® 7(11.3) 0.585 6(6.5) 1
Methylprednisolone pulse 2(18.2) 20(32.3) 0.486 4(30.8) 32(34.8) 1
Pos-transplantation dialysis 4(28.6) 14(15.9) 0.265 13(21) 0.195 1(7.7) 14(15.2) 0.687
Length of hospitalization in days 7 ± 2 8 ± 5 0.714 18 ± 22 17 ± 15 0.617 31 ± 36 23 ± 20 0.223
Serology
Hepatitis C virus 1(7.1) 7(8) 1 1(1.6) 1 4(30.8) 18(21.4) 0.462
Hepatitis B virus 4(4.5) 1 1(1.6) 1 1(7.7) 1(1.2) 0.236
Antimicrobial drugs 7(63.6) 31(50) 0.519 10(76.9) 69(75) 1
Vancomycin 1(9.1) 1(1.6) 0.28 3(23.1) 6(6.5) 0.081
Ganciclovir 6(9.7) 0.582 2(15.4) 10(10.8) 0.642
CAPD = chronic ambulatory peritoneal dialysis; HLA I = identical human leukocyte antigen;
HLA II = haplo-identical human leukocyte antigen; HLA III = distinct human leukocyte antigen;
Fisher and Student t tests were utilized for mean age and length of hospitalization;
Values are expressed as mean ± SD or N (%).BMC Infectious Diseases 2006, 6:133 http://www.biomedcentral.com/1471-2334/6/133
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are becoming emerging pathogens in context of human
disease.
Other studies have disclosed hemodialysis as an inde-
pendent risk factor for VRE colonization, including an
evaluation in our own dialysis facility [8,16] In fact, the
first cases of VRE were documented in hemodialysis
patients and an increasing prevalence of VRE colonization
has been reported by Tokars et al (11–34%) in American
hemodialysis centers between 1995 and 1999 [17].
Whether this reflects transmission within the dialysis
facilities or intrinsic patient conditions has yet to be deter-
mined. Although CAPD was a risk factor for VRE coloni-
zation in group 3 this finding should be interpreted with
great caution since only 3 patients from this group were
on CAPD at the time of transplantation and the present
study design differs from those that addressed the issue of
dialysis and VRE colonization.
Concerning the use of post-transplantation vancomycin,
it has been documented that there is a direct increase in
VRE prevalence, not only in relation to dialysis but also in
relation to transplantation [18,19]. Previous vancomycin
use is a known risk factor for VRE colonization and ICU
patients are particularly at risk. Recently, in an analysis of
the association between VRE and previous use of antimi-
crobial drugs, Fridkin et al. [10] found a statistically signif-
icant association between VRE colonization and previous
use of vancomycin among 126 adult ICUs in 60 American
hospitals.
In our study, previous use of vancomycin was an inde-
pendent risk factor for VRE colonization for Group 3
patients. In Group 2, out of the 73 patients studied, only
two of them had received vancomycin and only one of
these was VRE-positive (p = 0.28). In group 3, nine
patients out of 105 received vancomycin. Association
between vancomycin use and VRE colonization in this
group may reflect the cumulative use of vancomycin, since
the patients were followed for a longer period of time.
Restriction of vancomycin use in kidney transplant
patients has the clear advantage of preventing long term
VRE fecal colonization.
More intense immunosuppression is clearly linked with
higher rates of infection, especially with the use of high
steroid doses for rejection treatment and anti-lymphocyte
preparations [20,21]. Only one study showed a clear rela-
tionship between tacrolimus use and VRE colonization in
a mixed group of infants with end stage renal disease [22].
We have not found an association between presumed
more intense immunosuppression and VRE colonization,
including variables such as CMV infection, pulses of
methyl-prednisolone, OKT3 and MMF use. The net state
of immunosuppression seems to play a role in VRE colo-
nization, since higher rates are found in selected groups of
immune impaired patients, mainly ICU patients. How-
ever, whether immune suppression is a risk factor itself or
a surrogate marker for other risk factors remains to be
determined. It is our impression that more intense immu-
nosuppression among kidney transplant patients does not
play a central role in VRE colonization.
Although there is a strong correlation between coloniza-
tion and infection [23], during the study period we did
not observe any case of VRE infection among the studied
population. This must be explained by the fact that most
patients were colonized in the outpatient (or were dis-
charged shortly after colonization detection) setting
where other risk factors commonly associated with VRE
disease were not present.
This study has one important limitation. Two stool cul-
tures were planned for all patients; however, this goal was
achieved for 55 % of patients only although all efforts and
infrastructure for patient access to collection sites were
attempted were provided. This probably resulted in the
disclosure of an underestimated colonization rate consid-
ering that 24 % of all positive patients had the first speci-
men negative and the second positive.
Conclusion
VRE has become an important nosocomial pathogen
because of its rapid spread, high mortality rates associated
with infections, limited options for treatment and the
possibility of transferring resistance genes to vancomycin
to other more virulent and more prevalent pathogens
such as Staphylococcus aureus [24]. Strategies to promptly
identify colonized patients and apply contact precautions
have led to lower endemic rates in some studies [24].
Prompt identification is based on targeted surveillance,
considering risk factors for VRE colonization in selected
patients, mainly hospitalized ICU patients. We observed
an unexpectedly high rate of VRE colonization in kidney
transplant patients, which is very similar to those
observed in ICU's. Furthermore, a high rate of VRE colo-
nization from outpatients was shown, raising the ques-
tion of extending surveillance to recently admitted
patients from the ambulatory setting. It is our opinion
that due to cost concerns, this strategy could be reserved
for patients with known risk factors (recent of frequent
use of vancomycin) or to those with a higher probability
of transmission, such as patients with diarrhea.
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